Australia's most trusted
source of pharma news
Friday, 07 August 2026
Posted 7 August 2026 AM
Gilead has pushed off a challenge to more than $170 million in reimbursements for at least another year.
Alphapharm has agreed to an injunction against it supplying Dencovir, its generic version of Gilead's HIV drug Descovy, in Australia. It includes not supplying Dencovir in any way, and withdrawing its application to list Dencovir on the PBS.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.